Total Payments
$20,424
2024 Payments
$4,451
Companies
47
Transactions
1,054
Medicare Patients
3,316
Medicare Billing
$223,358
Payment Breakdown by Category
Food & Beverage$19,193 (94.0%)
Education$530.88 (2.6%)
Other$350.00 (1.7%)
Consulting$350.00 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $19,193 | 1,042 | 94.0% |
| Education | $530.88 | 10 | 2.6% |
| Honoraria | $350.00 | 1 | 1.7% |
| Consulting Fee | $350.00 | 1 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,388 | 125 | $0 (2024) |
| Janssen Biotech, Inc. | $2,172 | 117 | $0 (2024) |
| Galderma Laboratories, L.P. | $2,011 | 108 | $0 (2024) |
| PFIZER INC. | $1,406 | 87 | $0 (2024) |
| Lilly USA, LLC | $1,360 | 59 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,264 | 67 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $804.85 | 49 | $0 (2024) |
| GENZYME CORPORATION | $740.41 | 46 | $0 (2024) |
| UCB, Inc. | $717.26 | 32 | $0 (2024) |
| LEO Pharma Inc. | $698.69 | 39 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,451 | 209 | ABBVIE INC. ($780.41) |
| 2023 | $2,880 | 163 | Janssen Biotech, Inc. ($542.59) |
| 2022 | $3,018 | 183 | ABBVIE INC. ($417.84) |
| 2021 | $2,288 | 129 | Medimetriks Pharmaceuticals, Inc. ($405.04) |
| 2020 | $2,073 | 126 | MAYNE PHARMA INC. ($184.01) |
| 2019 | $2,289 | 114 | Galderma Laboratories, L.P. ($371.13) |
| 2018 | $1,841 | 85 | Galderma Laboratories, L.P. ($286.10) |
| 2017 | $1,583 | 45 | Biofrontera Inc. ($473.72) |
All Payment Transactions
1,054 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $8.65 | General |
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Immunology | ||||||
| 12/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | JUBLIA (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: Podiatry | ||||||
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $36.10 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: DERMATOLOGY | ||||||
| 12/05/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $13.44 | General |
| 12/04/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Immunology | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $6.74 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $32.20 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $2.09 | General |
| Category: Immunology | ||||||
| 11/21/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $27.76 | General |
| Category: DERMATOLOGY | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $25.51 | General |
| Category: Immunology | ||||||
| 11/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $32.08 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $9.81 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/13/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: Inflammation | ||||||
| 11/12/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.65 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: Immunology | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $25.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $9.13 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $11.92 | General |
| 11/04/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $3.39 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 851 | 1,606 | $182,593 | $59,913 |
| 2022 | 11 | 947 | 1,683 | $213,049 | $65,971 |
| 2021 | 13 | 835 | 1,309 | $183,374 | $57,587 |
| 2020 | 11 | 683 | 1,073 | $138,929 | $39,886 |
Total Patients
3,316
Total Services
5,671
Medicare Billing
$223,358
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 122 | 157 | $39,081 | $12,938 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 171 | 218 | $38,338 | $12,817 | 33.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 89 | 101 | $19,998 | $7,239 | 36.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 150 | 197 | $25,795 | $7,223 | 28.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 50 | 50 | $16,200 | $5,043 | 31.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 74 | 74 | $16,132 | $4,681 | 29.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 42 | 43 | $9,488 | $3,451 | 36.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 116 | 720 | $9,357 | $3,430 | 36.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 12 | 16 | $5,264 | $1,912 | 36.3% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 25 | 30 | $2,940 | $1,180 | 40.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 192 | 261 | $46,703 | $14,899 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 105 | 134 | $34,154 | $10,583 | 31.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 118 | 138 | $28,916 | $8,858 | 30.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 139 | 183 | $24,838 | $6,810 | 27.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 98 | 98 | $21,364 | $6,123 | 28.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 59 | 59 | $19,316 | $5,902 | 30.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 63 | 66 | $15,162 | $4,962 | 32.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 110 | 674 | $9,285 | $3,299 | 35.5% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 23 | 25 | $8,608 | $2,798 | 32.5% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 29 | 33 | $3,383 | $1,260 | 37.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 11 | 12 | $1,320 | $476.05 | 36.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 74 | 109 | $28,400 | $9,472 | 33.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 136 | 167 | $30,370 | $9,464 | 31.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 111 | 122 | $25,986 | $8,306 | 32.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 112 | 112 | $24,654 | $7,581 | 30.8% |
About Dr. Sarah Groff, MD
Dr. Sarah Groff, MD is a Dermatology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2013. The National Provider Identifier (NPI) number assigned to this provider is 1497192082.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sarah Groff, MD has received a total of $20,424 in payments from pharmaceutical and medical device companies, with $4,451 received in 2024. These payments were reported across 1,054 transactions from 47 companies. The most common payment nature is "Food and Beverage" ($19,193).
As a Medicare-enrolled provider, Groff has provided services to 3,316 Medicare beneficiaries, totaling 5,671 services with total Medicare billing of $223,358. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location San Antonio, TX
- Active Since 05/23/2013
- Last Updated 08/06/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1497192082
Products in Payments
- TREMFYA (Drug) $1,690
- DUPIXENT (Biological) $1,622
- TALTZ (Drug) $1,050
- EUCRISA (Drug) $974.81
- RINVOQ (Biological) $970.97
- COSENTYX (Biological) $589.64
- Humira (Biological) $537.82
- SKYRIZI (Biological) $528.78
- EPIDUO FORTE (Drug) $528.16
- AKLIEF (Drug) $505.39
- Ameluz (Drug) $489.64
- OPZELURA (Drug) $486.33
- Tremfya (Drug) $466.88
- CIBINQO (Drug) $431.23
- Otezla (Drug) $414.34
- Clindacin ETZ (Drug) $405.04
- Cimzia (Drug) $402.87
- Seysara (Drug) $372.34
- ENSTILAR (Drug) $361.91
- Sotyktu (Drug) $340.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in San Antonio
Dr. William Cragun, M.d, M.D
Dermatology — Payments: $1.9M
Dermatology $1.9M
Emily Becker, M.d, M.D
Dermatology — Payments: $937,773
Dermatology $937,773
Dr. Mark Lee, M.d, M.D
Dermatology — Payments: $589,973
Dermatology $589,973
Dr. Lindsey Finklea, M.d, M.D
Dermatology — Payments: $265,879
Dermatology $265,879
Steven Davis, Md, MD
Dermatology — Payments: $114,713
Dermatology $114,713
Stephen Miller, M.d. P.a, M.D. P.A
Dermatology — Payments: $89,896
Dermatology $89,896